Formulation Development for Transdermal Delivery of Raloxifene, a Chemoprophylactic Agent against Breast Cancer

• 主要な著者: Deepal Vora (著者), Amruta Dandekar (著者), Sonalika Bhattaccharjee (著者), Onkar N. Singh (著者), Vivek Agrahari (著者), M. Melissa Peet (著者), Gustavo F. Doncel (著者), Ajay K. Banga (著者)
• フォーマット: 図書
• 出版事項: MDPI AG, 2022-03-01T00:00:00Z.
• 主題: article
• オンライン･アクセス: Connect to this object online.

Raloxifene (RLX) is a second-generation selective estrogen receptor modulator approved for the prevention of invasive breast cancer in women. Oral therapy of RLX requires daily intake and is associated with side effects that may lead to low adherence. We developed a weekly transdermal delivery syste...